Furthermore, the KRAS c.35G>T (p.Gly12Val) mutation was associated with a poor immune response within the tumor microenvironment, characterized by lower tumor-infiltrating lymphocytes and higher tumor–stromal percentage, which exacerbates the aggressive nature of KRAS c.35G>T (p.Gly12Val) in mCRC [36]. This evidence concerns the gene KRAS and neoplasm.